What Peptides Did the FDA Panel Vote On in July 2026?

Short answer: On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides for the 503A Bulks List — and recommended six of them: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Only DSIP was not advanced. It's the strongest signal in years that peptide regulation is moving toward more regulated access, not less.

Status as of August 2026. This is a fast-moving regulatory story — this article carries a review-by date and will be re-verified. Disclosure: we're an authorized reseller of products sold under the InstaMed brand (Salt Lake City / Draper, Utah), so we have a commercial interest in this category. Read us accordingly.

Why this meeting matters

For years, the peptide story was mostly about restriction. July 2026 reads differently: a standing FDA advisory committee — outside experts from industry, academia, state regulators, the US Pharmacopeia, and clinicians — looked at seven nominated peptides and voted to recommend six for the compounding bulks list. Per McDermott Will & Emery's meeting coverage, each substance followed a fixed format: public speakers, a presentation by FDA's own scientists, committee Q&A, and a vote.

It's part of a visible pattern of re-examination. NMN's dietary-supplement eligibility was formally reinstated by FDA in late 2025 after years of exclusion — eligibility restored, rules actively being rewritten. The July votes fit that same direction of travel: the category is being brought inside a regulated framework rather than pushed further out.

One striking detail from the record: FDA's career scientists recommended against all seven substances, citing thin human data — and the committee voted the other way on six anyway. The outside experts saw enough promise to overrule the staff position [regulatory record — McDermott Will & Emery meeting coverage, July 2026].

The votes, compound by compound

Per the published vote record as reported by McDermott Will & Emery (consistent with this program's research dossier):

Day 1 — July 23, 2026

Day 2 — July 24, 2026

Note what FDA evaluated each substance for — those are the nominated uses on the official meeting agenda (FDA.gov), not the popular uses people actually discuss. BPC-157 was assessed for ulcerative colitis while most consumer interest is recovery. That mismatch is worth remembering when reading headlines — and it cuts in the encouraging direction: the committee saw value even in the narrow, formal use cases.

What happens next

Per law-firm and trade coverage (McDermott; NCPA, July 31, 2026):

1. FDA initiates notice-and-comment rulemaking to formally add recommended substances to the 503A Bulks List. This could conclude in 2027 or stretch longer — our research dossier pegs lawful compounding of BPC-157/TB-500 at roughly mid-to-late 2027 at the earliest.
2. Interim movement is possible. Coverage notes the HHS Secretary could add substances to Category 1 (interim enforcement discretion) pending rulemaking — a lever that now exists because of these votes.
3. A second PCAC meeting is scheduled before the end of February 2027 covering GHK-Cu, Dihexa acetate, cathelicidin LL-37, PEG-MGF, and Melanotan II. The momentum continues.
4. Pharmacies cannot compound these peptides yet — that changes only at final rulemaking (NCPA).

The honest passage

One bounded paragraph, because precision matters on a story moving this fast: a PCAC recommendation is advisory and non-binding — it is not approval, not rulemaking, and it changes nothing that can be lawfully compounded today. FDA has overridden advisory votes before, and rulemaking can stall. Anyone marketing "FDA approved peptides are back" is wrong as of August 2026. That said — the vote record above is real, the direction is documented, and that's the news.

What this means for each compound's buyers

• BPC-157: the strongest headline. If rulemaking lands, it becomes compoundable by prescription — timeline 2027+. Our compound explainer on BPC-157 covers the evidence base separately from the politics.
• TB-500 and KPV: both recommended 8–6. Neither exists as a standalone retail product in the line we resell; both live inside the KLOW blend (TB-500 300 mcg, KPV 500 mcg per strip) — see what KLOW actually is. KLOW is available at open checkout.
• MOTS-c: recommended 7–5, the narrowest yes of day one. It appears in the BOOST SKU, available at open checkout. Our earlier piece on MOTS-c in sublingual format covers the format question.
• Semax and Epitalon: recommended on day two. Semax appears in the NEURO blend in its N-acetyl form.
• DSIP (emideltide): the one substance not advanced, 6–7. Nominations can return — the process that re-examined these seven can revisit an eighth. The SLEEP SKU we reference (DSIP + GABA + 5-HTP) is available at open checkout, and the sleep peptide strips overview explains the category framing.

The bottom line

Six of seven peptides recommended, staff objections overruled by the committee, a follow-up meeting already on the calendar, and NMN's reinstatement fresh in the record — the regulatory direction for peptides in 2026 is toward structured, legitimate access. Nothing is finalized, and that's exactly why this story is worth tracking: the framework being built now is the one these compounds will live in. For the broader picture, see our safety and sourcing guide, FDA status of BPC-157 in 2026, and our 2026 peptide legality overview.

Two of the compounds on that agenda already exist in the supplement lane as strips — BPC-157 and MOTS-c — which is a different regulatory track from compounding, and worth keeping distinct as the rulemaking proceeds.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.